logo

Regeneron Pharmaceuticals (REGN)



Trade REGN now with
  Date
  Headline
6/6/2018 7:02:00 AM Regeneron And Zoetis Announce Five-year Collaboration To Research Antibody Therapies For Use In Animal Health
5/16/2018 1:02:42 AM Regeneron, Sanofi: Pivotal Phase 3 Trial Evaluating DUPIXENT Met Its Primary And Key Secondary Endpoints
5/7/2018 10:15:28 AM RBC Capital Markets Is Increasing Regeneron Pharmaceuticals (REGN) 4Q18 Estimate To 5.05 From 3.82
5/7/2018 10:15:19 AM RBC Capital Markets Is Increasing Regeneron Pharmaceuticals (REGN) 3Q18 Estimate To 4.78 From 3.64
5/7/2018 10:14:59 AM RBC Capital Markets Is Lowering Regeneron Pharmaceuticals (REGN) 4Q18 Rev. Estimate To 1609.0 M From 1701.0 M
5/7/2018 10:14:49 AM RBC Capital Markets Is Cutting Regeneron Pharmaceuticals (REGN) 3Q18 Rev. Estimate To 1565.0 M From 1649.0 M
5/7/2018 10:14:31 AM RBC Capital Markets Is Lowering Regeneron Pharmaceuticals (REGN) 2Q18 Rev. Estimate To 1532.0 M From 1598.0 M
5/7/2018 10:14:09 AM RBC Capital Markets Is Increasing Regeneron Pharmaceuticals (REGN) 2020 Estimate To 24.24 From 18.07
5/7/2018 10:13:59 AM RBC Capital Markets Is Increasing Regeneron Pharmaceuticals (REGN) 2019 Estimate To 23.36 From 16.54
5/7/2018 10:13:49 AM RBC Capital Markets Is Raising Regeneron Pharmaceuticals (REGN) 2018 Estimate To 18.39 From 13.95
5/7/2018 10:13:34 AM RBC Capital Markets Is Cutting Regeneron Pharmaceuticals (REGN) 2020 Rev. Estimate To 7751 M From 7758 M
5/7/2018 10:13:22 AM RBC Capital Markets Is Raising Regeneron Pharmaceuticals (REGN) 2019 Rev. Estimate To 7272.0 M From 7178.0 M
5/7/2018 10:13:06 AM RBC Capital Markets Is Lowering Regeneron Pharmaceuticals (REGN) 2018 Rev. Estimate To 6218.0 M From 6493.0 M
5/3/2018 6:32:03 AM Regeneron Q1 GAAP EPS Up 93% To $4.16; Non-GAAP EPS Up 60% To $4.67